Clinical Trial Update: Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) [Phase 3]

View source ↗

Summary

Phase 3 BRANT trial evaluating the efficacy and safety of tirofiban in patients with Branch Atheromatous Disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Atheromatous Disease

Drugs mentioned

• tirofiban (Aggrastat) (tirofiban)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Branch Atheromatous Disease | Phase 3 | Status: COMPLETED